Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2020

Open Access 01-02-2020 | Colorectal Cancer | Clinical Guides in Oncology

SEOM clinical guideline for secondary prevention (2019)

Authors: A. Santaballa, Á. Pinto, R. P. Balanyà, N. Ramírez Merino, I. R. Martín, S. S. Grau, J. P. B. Fombella, J. M. Cano, C. H. González, J. Bayo

Published in: Clinical and Translational Oncology | Issue 2/2020

Login to get access

Abstract

Cancer is one of the major public health problems in our society. It is estimated that more than 18 million new cases are diagnosed worldwide every year; 280,000 in Spain. Incidence in following a growing trend. This epidemic could be controlled with research into new treatments and, above all, with adequate prevention. Primary prevention could prevent avoid up to half of all cases. For many others, secondary prevention is essential, as it make diagnosis possible in the stages of the disease when it is easily curable. These guidelines present the scientific evidence regarding secondary prevention in tumors in which its use is well-accepted: breast, cervical, colorectal, prostate, lung, ovarian, melanoma, and gastric cancer.
Literature
1.
2.
3.
Organización Mundial de la Salud. Promoción de la Salud Glosario. Organ Mund La Salud. 1998;1–35.
4.
Manual SEOM de prevención y diagnóstico precoz del cáncer. Coordinación Dr. Juan Bayo Calero. SEOM 2017. ISBN 978-84-697-4630-1.
5.
Oeffinger KC, Fontham ET, Etzioni R, Herzig A, Michaelson JS, Shih YC, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society [published correction appears in JAMA. 2016 Apr 5;315(13):1406]. JAMA. 2015;314(15):1599–614.CrossRef
6.
Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 US preventive services task force recommendation. Ann Intern Med. 2016;164(4):244–55. https://​doi.​org/​10.​7326/​m15-0969(Epub 2016 Jan 12).CrossRefPubMed
7.
Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer. 2012;107(1):24–30.CrossRef
8.
Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst. 2002;94(19):1445–57.CrossRef
9.
Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomatarn I, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. Lancet Oncol. 2019;20:394–407.CrossRef
10.
Arbyn M, Anttila A, De Vuyst H, Dillner J, Dillner L, Franceschi S et al. European guidelines for quality assurance in cervical cancer screening. Second edition—Supplements. European Union, 2015.
11.
12.
Rex DK, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colorectal cancer screening: Recommendations for physicians and patients from the Manual SEOM de prevención y diagnóstico precoz del cáncer. Coordinación Dr U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153:307–23.CrossRef
13.
Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68:250–81.CrossRef
14.
Lauby-Secretan B, Vilahur N, Bianchini F, Guha N, Straif K, International Agency for Research on Cancer Handbook Working Group. The IARC perspective on colorectal cancer screening. N Engl J Med. 2018;378:1734–40.CrossRef
15.
Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1:CD004720.
16.
Wolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70.CrossRef
17.
Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;19:1901–13.
18.
Ministerio de Sanidad, Servicios Sociales e Igualdad. Muertes atribuibles al consumo de tabaco en España, 2000–2014. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad, 2017.
19.
The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.CrossRef
20.
Field JK, Duffy SW, Baldwin DR, Brain KE, Devaraj A, Eisen T, Green BA, Holemans JA, Kavanagh T, Kerr KM, Ledson M, Lifford KJ, McRonald FE, Nair A, Page RD, Parmar MK, Rintoul RC, Screaton N, Wald NJ, Weller D, Whynes DK, Williamson PR, Yadegarfar G, Hansell DM. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health Technol Assess. 2016;20(40):1–146.CrossRef
21.
Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, Sverzellati N, Sozzi G, Corrao G, Marchianò A. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019;30(7):1162–9.CrossRef
22.
Humphrey LL, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, Zakher B, Fu R, Slatore CG. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med. 2013;159(6):411–20.CrossRef
23.
Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel CP, Bastarrika G, Sverzellati N, Mascalchi M, Delorme S, Baldwin DR, Callister ME, Becker N, Heuvelmans MA, Rzyman W, Infante MV, Pastorino U, Pedersen JH, Paci E, Duffy SW, de Koning H, Field JK. European position statement on lung cancer screening. Lancet Oncol. 2017;18(12):e754–66.CrossRef
24.
Van Nagell JR, Miller RW, De Simone CP, et al. Long term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol. 2011;118(6):1212–21.CrossRef
25.
26.
Llort G, Chirivella I, Morales R, Serrano R, Sanchez AB, Teulé A, Lastra E, Brunet J, Balmaña J, Graña B. SEOM clinical guidelines in hereditary breast and ovarian cancer. Clin Transl Oncol. 2015;17(12):956–61.CrossRef
Metadata
Title
SEOM clinical guideline for secondary prevention (2019)
Authors
A. Santaballa
Á. Pinto
R. P. Balanyà
N. Ramírez Merino
I. R. Martín
S. S. Grau
J. P. B. Fombella
J. M. Cano
C. H. González
J. Bayo
Publication date
01-02-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 2/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02302-0

Other articles of this Issue 2/2020

Clinical and Translational Oncology 2/2020 Go to the issue

Clinical Guides in Oncology

SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)

Editorial

2019 SEOM guidelines (the end of a decade)

Clinical Guides in Oncology

SEOM clinical guideline thyroid cancer (2019)

Clinical Guides in Oncology

SEOM clinical guidelines for cervical cancer (2019)

Clinical Guides in Oncology

SEOM clinical guideline on hereditary colorectal cancer (2019)

Clinical Guides in Oncology

SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits